Aspirin; pentazocine hydrochloride - Generic Drug Details

What are the generic drug sources for aspirin; pentazocine hydrochloride and what is the scope of freedom to operate?

Aspirin; pentazocine hydrochloride is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for aspirin; pentazocine hydrochloride

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
DailyMed Link:	aspirin; pentazocine hydrochloride at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for aspirin; pentazocine hydrochloride

N02AD	Benzomorphan derivatives
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

US Patents and Regulatory Information for aspirin; pentazocine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	TALWIN COMPOUND	aspirin; pentazocine hydrochloride	TABLET;ORAL	016891-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for aspirin; pentazocine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	TALWIN COMPOUND	aspirin; pentazocine hydrochloride	TABLET;ORAL	016891-001	Approved Prior to Jan 1, 1982	4,105,659

Aspirin and Pentazocine Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 18, 2026

Aspirin, a foundational non-steroidal anti-inflammatory drug (NSAID), and pentazocine hydrochloride, an opioid analgesic, represent distinct market segments within the pharmaceutical landscape. Aspirin's market is characterized by widespread generic availability, high volume, and consistent demand driven by its broad therapeutic applications. Pentazocine hydrochloride operates within a more specialized, albeit regulated, segment, primarily addressing moderate to severe pain. This analysis examines their respective market dynamics, patent landscapes, and financial trajectories.

Aspirin: A Mature Generic Market

What is Aspirin's Core Therapeutic Role and Market Size?

Aspirin, chemically acetylsalicylic acid, is primarily used as an analgesic, antipyretic, and anti-inflammatory agent. Its low-dose formulation also plays a critical role in cardiovascular disease prevention by inhibiting platelet aggregation. The global market for aspirin is substantial, driven by its over-the-counter (OTC) availability and inclusion in essential medicines lists worldwide.

• Therapeutic Applications: Pain relief (headache, muscle aches, dental pain), fever reduction, reduction of inflammation, prevention of heart attack and stroke in at-risk individuals.
• Estimated Market Size: While precise, up-to-the-minute figures for pure aspirin are challenging due to its commoditized nature and inclusion in combination products, the global NSAID market, of which aspirin is a significant component, was valued at approximately $23.4 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 3.5% through 2030 [1]. Aspirin's share within this is substantial, particularly in OTC segments.

What is the Patent and Intellectual Property Landscape for Aspirin?

Aspirin was first synthesized in 1853 and patented by Bayer in 1899. Its original patents have long expired, placing it firmly in the public domain. This absence of patent protection has led to widespread generic competition.

• Patent Expiry: Original composition of matter patents expired over a century ago.
• Generic Competition: Numerous pharmaceutical companies manufacture and market generic aspirin. This intense competition has driven down prices and established a highly price-sensitive market.
• Limited New IP: While novel formulations or delivery methods for aspirin might attract limited intellectual property protection, the core molecule does not benefit from patent exclusivity. Research into new therapeutic indications for aspirin continues, but patenting these discoveries is challenging given its long history and extensive use.

What are the Key Market Drivers and Restraints for Aspirin?

The sustained demand for aspirin is influenced by several factors, alongside certain limitations.

• Market Drivers:
  • Affordability: Generic aspirin is one of the most affordable pain relief medications available.
  • Accessibility: Widely available in pharmacies, supermarkets, and convenience stores globally.
  • Established Efficacy and Safety Profile: Decades of clinical use have established its efficacy and a well-understood safety profile (when used appropriately).
  • Cardiovascular Prevention: The recommendation for low-dose aspirin for secondary cardiovascular prevention in specific patient populations ensures consistent demand.
  • Aging Population: A growing elderly population, often with chronic pain and increased risk of cardiovascular events, contributes to sustained demand.
• Market Restraints:
  • Gastrointestinal Side Effects: The risk of gastric irritation, ulcers, and bleeding is a significant concern, particularly with regular use.
  • Reye's Syndrome: Contraindicated in children and adolescents with viral infections due to the risk of Reye's syndrome.
  • Competition from Newer NSAIDs and Analgesics: Newer NSAIDs with potentially better safety profiles or alternative analgesics offer substitutes.
  • Price Sensitivity: The generic nature of the market limits profit margins for manufacturers.

What is the Financial Trajectory of Aspirin Manufacturers?

Manufacturers of generic aspirin operate on low-margin, high-volume models. Profitability is driven by production efficiency, supply chain management, and market penetration.

• Revenue Streams: Primarily derived from bulk sales to distributors, pharmacies, and healthcare systems. Contract manufacturing for private label brands is also a significant revenue source.
• Profitability: Margins are typically thin, often in the low to mid-single digits percentage-wise. Success relies on economies of scale and cost optimization.
• Investment Focus: Investment in this segment focuses on optimizing manufacturing processes, ensuring regulatory compliance, and maintaining robust distribution networks rather than novel R&D.

Pentazocine Hydrochloride: A Regulated Analgesic Market

What is Pentazocine Hydrochloride's Therapeutic Role and Market Position?

Pentazocine hydrochloride is a synthetic opioid analgesic used to treat moderate to severe pain. It acts as a mixed agonist-antagonist at opioid receptors, providing pain relief while potentially having a ceiling effect on respiratory depression and a lower potential for dependence compared to pure mu-opioid agonists like morphine, though dependence is still a significant risk.

• Therapeutic Applications: Management of moderate to severe pain, often when other analgesics are insufficient. It is available in various formulations, including injectable, oral, and parenteral.
• Market Classification: Pentazocine is classified as a Schedule IV controlled substance by the U.S. Drug Enforcement Administration (DEA) due to its potential for abuse and dependence [2]. This classification significantly impacts its market access, prescribing practices, and distribution.
• Estimated Market Size: The market for pentazocine hydrochloride is considerably smaller than that of aspirin and is part of the broader opioid analgesic market. The global opioid analgesics market was valued at an estimated $16.6 billion in 2022, with a projected CAGR of 3.2% from 2023 to 2030 [3]. Pentazocine's specific contribution is difficult to isolate but is a niche within this segment, facing competition from other Schedule IV and III opioids, as well as non-opioid alternatives.

What is the Patent and Intellectual Property Landscape for Pentazocine Hydrochloride?

Pentazocine was developed by Sterling Drug (now part of Sanofi) and first introduced in the 1960s. The original patents for pentazocine have long expired. However, intellectual property activity around pentazocine has focused on specific formulations, combinations, and manufacturing processes.

• Original Patent Expiry: The foundational patents expired decades ago.
• Formulation and Combination Patents: Companies have sought and obtained patents for specific pharmaceutical compositions, such as combinations with naloxone (e.g., Talwin NX) to deter abuse, or novel delivery systems. These patents provide limited exclusivity for specific product variants.
  • Example: Talwin NX (pentazocine hydrochloride and naloxone hydrochloride tablets) has been subject to patent protection for its abuse-deterrent formulation. Expiry dates for such formulation patents can extend beyond the molecule's original patent expiry.
• Generic Entry: Generic versions of pentazocine hydrochloride are available, but their market penetration is influenced by the regulatory hurdles and the complexity of prescription and dispensing due to its controlled substance status.

What are the Key Market Drivers and Restraints for Pentazocine Hydrochloride?

The market for pentazocine hydrochloride is shaped by its therapeutic utility, regulatory environment, and the evolving landscape of pain management.

• Market Drivers:
  • Treatment of Moderate to Severe Pain: Addresses a significant unmet need for effective pain management in patients who do not respond adequately to non-opioid analgesics.
  • Abuse-Deterrent Formulations: Innovations like the combination with naloxone aim to reduce the potential for abuse, making it a more acceptable option for some prescribers and patients.
  • Controlled Substance Efficacy: It provides a proven analgesic effect for specific pain profiles.
• Market Restraints:
  • Regulatory Scrutiny and Control: Its Schedule IV classification imposes strict regulations on manufacturing, distribution, prescribing, and dispensing, increasing compliance costs and limiting market reach.
  • Potential for Abuse and Dependence: Despite being a mixed agonist-antagonist, it still carries a risk of abuse, dependence, and addiction, which drives conservative prescribing practices.
  • Side Effects: Common side effects include dizziness, nausea, vomiting, drowsiness, and potential for dysphoria or hallucinations.
  • Competition from Other Opioids and Non-Opioids: Faces competition from other Schedule III and IV opioids, as well as emerging non-opioid pain management therapies.
  • Stigma Associated with Opioids: The broader societal concerns and stigma surrounding opioid use can influence physician prescribing habits and patient willingness to use these medications.
  • Prescribing Restrictions: Many healthcare systems and insurers have implemented prior authorization requirements and quantity limits for opioid prescriptions, including pentazocine.

What is the Financial Trajectory of Pentazocine Hydrochloride Manufacturers?

Manufacturers of pentazocine hydrochloride, whether original innovators or generic producers, operate in a more complex financial environment compared to pure generic aspirin producers.

• Revenue Streams: Sales revenue is generated from branded and generic formulations sold to pharmacies, hospitals, and distributors. Revenue is influenced by prescription volume, pricing, and market exclusivity for specific formulations.
• Profitability: Profitability is generally higher per unit than for aspirin due to specialized formulation, regulatory compliance costs, and less intense price competition among approved products. However, the market volume is significantly lower.
• Investment Focus: Investment is directed towards maintaining manufacturing compliance with DEA regulations, developing abuse-deterrent formulations, and navigating the complex regulatory approval and marketing processes for controlled substances. R&D may focus on novel combinations or improved delivery systems rather than new molecular entities.
• Market Value: The financial value of a pentazocine hydrochloride product line is influenced by its market share within its niche, patent protection on its specific formulations, and the ongoing regulatory landscape for controlled substances.

Comparative Analysis: Aspirin vs. Pentazocine Hydrochloride

Feature	Aspirin	Pentazocine Hydrochloride
Therapeutic Class	NSAID, Analgesic, Antipyretic, Anti-inflammatory, Antiplatelet	Opioid Analgesic (Mixed Agonist-Antagonist)
Primary Market	Broad OTC and prescription use for pain, fever, inflammation, CVD prevention	Prescription-only for moderate to severe pain
Patent Status	Expired; public domain	Original patents expired; IP protection on specific formulations/combinations
Market Competition	Highly competitive generic market	Less intense competition, but regulated by controlled substance status
Regulatory Status	Widely available, minimal restrictions	Schedule IV controlled substance (U.S. DEA)
Market Volume	Very high	Moderate to low
Price Sensitivity	High	Moderate
Profit Margins	Low	Moderate to high per unit, but lower total revenue due to volume
R&D Focus	Manufacturing efficiency, new indications (limited IP)	Abuse-deterrent formulations, novel combinations, regulatory compliance
Risk Profile	GI issues, Reye's syndrome (in children)	Abuse, dependence, addiction, CNS side effects
Key Drivers	Affordability, accessibility, established efficacy, CVD prevention	Efficacy for severe pain, abuse-deterrent formulations
Key Restraints	Side effects, competition from newer drugs	Regulatory hurdles, abuse potential, stigma, side effects

Key Takeaways

Aspirin and pentazocine hydrochloride represent two vastly different segments of the pharmaceutical market. Aspirin thrives in a high-volume, low-margin generic environment driven by broad accessibility and established utility, particularly in OTC and cardiovascular applications. Its financial trajectory is tied to manufacturing efficiency and scale. Pentazocine hydrochloride operates in a niche, prescription-only market for moderate to severe pain. Its financial performance is constrained by its controlled substance status, regulatory complexities, and potential for abuse, but offers higher per-unit margins and relies on IP for specific formulations and abuse-deterrent features.

Frequently Asked Questions

1. What is the primary reason for aspirin's continued market dominance despite its age? Aspirin's market dominance stems from its low cost, widespread availability as an over-the-counter medication, established efficacy for a range of common ailments, and its critical role in cardiovascular disease prevention, all underpinned by expired patents that allow for extensive generic competition.

2. How does the Schedule IV classification of pentazocine hydrochloride impact its market access and profitability? The Schedule IV classification restricts pentazocine hydrochloride's distribution, prescribing, and dispensing, necessitating significant compliance infrastructure. This regulatory oversight limits overall market volume but also creates barriers to entry for potential competitors and can support higher pricing for approved, compliant products, thereby influencing profitability on a per-unit basis.

3. Are there significant opportunities for new intellectual property development for aspirin? Opportunities for new intellectual property for aspirin are limited. While novel formulations, delivery systems, or newly discovered therapeutic indications could theoretically be patented, the extensive prior art and the fundamental nature of aspirin make robust and lasting patent protection challenging to secure and defend.

4. What is the competitive landscape for pentazocine hydrochloride, and how does it differ from aspirin's? Pentazocine hydrochloride competes with other Schedule III and IV opioid analgesics and a growing array of non-opioid pain management therapies. The competition is less about direct price wars driven by generic entry (as with aspirin) and more about clinical efficacy profiles, safety considerations, abuse deterrence, and navigating prescribing guidelines and formularies influenced by its controlled substance status.

5. Given the mature nature of both drugs, what are the primary financial considerations for manufacturers in these respective markets? For aspirin manufacturers, the primary financial consideration is achieving economies of scale in production and distribution to maintain profitability in a highly price-competitive, low-margin market. For pentazocine hydrochloride manufacturers, financial success depends on effectively managing regulatory compliance costs, leveraging any intellectual property for specific formulations, and achieving sufficient market penetration within its constrained therapeutic niche, where per-unit margins are higher but overall volume is lower.

Citations

[1] Grand View Research. (2023). NSAIDs Market Size, Share & Trends Analysis Report By Drug Class (COX-2 Inhibitors, Non-selective NSAIDs), By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/nsaids-market

[2] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act - Schedules of Controlled Substances. Retrieved from https://www.dea.gov/controlled-substances-schedule

[3] Precedence Research. (2023). Opioid Analgesics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2032. Retrieved from https://www.precedenceresearch.com/opioid-analgesics-market